Jia Xi-shuai, Zhou Shui-mao, Xu Ming-xing, Yang Yan, Wu Kai
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2016 Dec;34(6):489-92.
To identify Plasmodium falciparum multidrug resistance 1（Pfmdr1） point mutations in imported Plasmodium falciparum in Wuhan.
Blood samples were collected from returnees infected with P. falciparum in endemic areas of Africa and Myanmar during 2010-2015 in Wuhan City. Nested PCR primers were specifically designed for Pfmdr1 gene loci 86, 1042 and 1246 of P. falciparum. The Pfmdr1 gene was then amplified by nested PCR, and the products were digested by restriction enzyme ApoⅠ, AseⅠ and EcoRⅤ, respectively. The mutation rate for loci 86, 1042 and 1246 was analyzed. Results A total of 187 patients with falciparum malaria were involved in the study. Pfmdr1 was amplified from all the blood samples. Restriction enzyme digestion revealed mutation rate of 19.3%（36/187）, 4.3% （8/187） and 9.6%（18/187） for loci 86, 1042 and 1246, respectively. In detail, the mutation rate for loci 86, 1042 and 1246 was 20.6%（36/175）, 2.9%（5/175） and 10.3%（18/175） respectively in the 175 samples from Africa, and only 3 cases with locus 1042 mutation were found in the 12 samples from Myanmar.
A total of 187 patients with falciparum malaria were involved in the study. Pfmdr1 was amplified from all the blood samples. Restriction enzyme digestion revealed mutation rate of 19.3%（36/187）, 4.3% （8/187） and 9.6%（18/187） for loci 86, 1042 and 1246, respectively. In detail, the mutation rate for loci 86, 1042 and 1246 was 20.6%（36/175）, 2.9%（5/175） and 10.3%（18/175） respectively in the 175 samples from Africa, and only 3 cases with locus 1042 mutation were found in the 12 samples from Myanmar.
The loci 86, 1042 and 1246 mutations of Pfmdr1 have all been found in the samples from Africa, with only one point mutation （locus 1042） found in samples from Myanmar.
鉴定武汉输入性恶性疟原虫中恶性疟原虫多药耐药基因1（Pfmdr1）的点突变情况。
收集2010 - 2015年期间武汉市从非洲和缅甸疟疾流行区回国且感染恶性疟原虫的归国人员的血样。针对恶性疟原虫Pfmdr1基因86、1042和1246位点设计巢式PCR引物。然后通过巢式PCR扩增Pfmdr1基因，产物分别用限制性内切酶ApoⅠ、AseⅠ和EcoRⅤ进行酶切。分析86、1042和1246位点的突变率。结果 共187例恶性疟患者参与本研究。所有血样均扩增出Pfmdr1基因。酶切结果显示，86、1042和1246位点的突变率分别为19.3%（36/187）、4.3%（8/187）和9.6%（18/187）。具体而言，来自非洲的175份样本中，86、1042和1246位点的突变率分别为20.6%（36/175）、2.9%（5/175）和10.3%（18/175），而来自缅甸的12份样本中仅发现3例1042位点突变。
共187例恶性疟患者参与本研究。所有血样均扩增出Pfmdr1基因。酶切结果显示，86、1042和1246位点的突变率分别为19.3%（36/187）、4.3%（8/187）和9.6%（18/187）。具体而言，来自非洲的175份样本中，86、1042和1246位点的突变率分别为20.6%（36/175）、2.9%（5/175）和10.3%（18/175），而来自缅甸的12份样本中仅发现3例1042位点突变。
Pfmdr1基因的86、1042和1246位点突变在非洲样本中均有发现，缅甸样本中仅发现1个点突变（1042位点）。
